The file room
Every story on file, newest first. Filter by bay, region or how far a plant has got.
10 of 33 stories · sheet 1 of 2
B3Trade
Torrent Pharmaceuticals hopes to launch generic semaglutide in Brazil in six to nine months, joining a market where EMS already has an approved pen. It has not named the manufacturer, after a supply gap in India.
B3Trade
A Treasury draft under the COINS Act adds biotechnology, including biomanufacturing equipment and facilities, to US outbound investment screening. Comments are due 7 December; the start date comes later.
B2Process
DuPont launched a C8 and C18 silica medium for crude cleanup and final polishing of GLP 1 and other peptides, designed to run alongside its polymer resins. No price, plant or performance data were published.
B3Trade
The White House said branded and patented medicines made abroad would face a 100% tariff from October 1, unless the maker is building a plant in the United States.
B2Process
One of Lilly's four new US sites will make orforglipron, a once-a-day pill that acts on the GLP-1 receptor but is not a peptide.
B1Plants
Lilly said it would build four new US sites, more than doubling its US manufacturing spend since 2020 to about $50 billion.
B1Plants
The new building adds sterile filling and finishing in a town where Novo already makes medicines. About 1,000 jobs are expected.
B4Deals
Lilly agreed to buy a finished plant near the Illinois border from Nexus Pharmaceuticals. The price was not disclosed.
